Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial

This study is looking for adults aged 18 or over who have had a serious injury and are admitted to an intensive care unit. You would need to be expected to stay in intensive care for more than two days and be planning to receive low-molecular-weight heparin, like Enoxaparin, to prevent blood clots. You would also need to be part of the French or European social security system.

There are several reasons why someone might not be able to join the study. For example, if you had a heart attack before coming to the hospital, or if more than three days have passed since your injury. You also couldn't take part if you've already received more than one dose of blood thinner since your injury.

Other reasons for not being able to join include having serious kidney problems, being very underweight (less than 7 stone) or very overweight (more than 15 stone 10 pounds), needing blood thinners for another medical condition, having certain blood clotting disorders, very low blood platelet counts, or a history of bad reactions to heparin. Severe bleeding, recent brain or spine surgery, pregnancy, breastfeeding, or being part of another experimental trial would also prevent participation.

If you join this study, you would receive either the standard dose or an intermediate (slightly higher) dose of Enoxaparin, given as an injection, to prevent blood clots. It's a 'double blind' study, meaning neither you nor your doctors would know which dose you are receiving. Your medical team would closely monitor your health, looking for any signs of blood clots or bleeding. The total duration of your participation would depend on your hospital stay and recovery, but the blood thinning medicine would be given for as long as deemed necessary after your trauma.